Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies

Ibrutinib is a first-generation inhibitor of Bruton tyrosine kinase (BTK) that is currently approved to treat patients with B-cell malignancies, including Waldenström macroglobulinemia (WM), relapsed/refractory (R/R) mantle cell lymphoma (MCL), R/R marginal zone lymphoma (MZL), and chronic lymphocyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz, Javier, Sarosiek, Shayna, Castillo, Jorge J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Hematologic Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078910/
https://www.ncbi.nlm.nih.gov/pubmed/36723874
http://dx.doi.org/10.1093/oncolo/oyac260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078910/
https://www.ncbi.nlm.nih.gov/pubmed/36723874
http://dx.doi.org/10.1093/oncolo/oyac260

Ejemplares similares